{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:02:54Z","timestamp":1780628574247,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,3]]},"DOI":"10.7759\/cureus.21885","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T22:06:52Z","timestamp":1643926012000},"source":"Crossref","is-referenced-by-count":13,"title":["Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines"],"prefix":"10.7759","author":[{"given":"Hannah","family":"Saven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynna","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel M","family":"McFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual\u00a0antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno D","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC\/AHA versus ESC guidelines on dual\u00a0antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018, 72:2915-31. 10.1016\/j.jacc.2018.09.057","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused\u00a0update on duration of dual\u00a0antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines","volume":"68","author":"Levine GN","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al.. 2016 ACC\/AHA guideline focused\u00a0update on duration of dual\u00a0antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task\u00a0Force\u00a0on\u00a0Clinical Practice Guidelines. J Am Coll Cardiol. 2016, 68:1082-115. 10.1016\/j.jacc.2016.03.513","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2165\/11640880-000000000-00000","article-title":"The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day","volume":"72","author":"Angiolillo DJ","year":"2012","unstructured":"Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012, 72:2087-116. 10.2165\/11640880-000000000-00000","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.686048","article-title":"Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment","volume":"116","author":"Airoldi F","year":"2007","unstructured":"Airoldi F, Colombo A, Morici N, et al.. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007, 116:745-54. 10.1161\/CIRCULATIONAHA.106.686048","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.600155","article-title":"Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents","volume":"113","author":"Kuchulakanti PK","year":"2006","unstructured":"Kuchulakanti PK, Chu WW, Torguson R, et al.. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006, 113:1108-13. 10.1161\/CIRCULATIONAHA.105.600155","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based\u00a0on ischemic and bleeding risks after coronary\u00a0stenting","volume":"73","author":"Costa F","year":"2019","unstructured":"Costa F, Van Klaveren D, Feres F, et al.. Dual antiplatelet therapy duration based\u00a0on ischemic and bleeding risks after coronary\u00a0stenting. J Am Coll Cardiol. 2019, 73:741-54. 10.1016\/j.jacc.2018.11.048","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2019.09","article-title":"Dual antiplatelet therapy in coronary artery disease: comparison between ACC\/AHA 2016 and ESC 2017 guidelines","volume":"15","author":"Floyd CN","year":"2020","unstructured":"Floyd CN. Dual antiplatelet therapy in coronary artery disease: comparison between ACC\/AHA 2016 and ESC 2017 guidelines. Eur Cardiol. 2020, 15:1-3. 10.15420\/ecr.2019.09","journal-title":"Eur Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318202f701","article-title":"ACCF\/ACG\/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents","volume":"122","author":"Abraham NS","year":"2010","unstructured":"Abraham NS, Hlatky MA, Antman EM, et al.. ACCF\/ACG\/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010, 122:2619-33. 10.1161\/CIR.0b013e318202f701","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli M","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al.. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018, 39:213-60. 10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt DL","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, et al.. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010, 363:1909-17. 10.1056\/NEJMoa1007964","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1795","article-title":"Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group","volume":"171","author":"Barkun AN","year":"2019","unstructured":"Barkun AN, Almadi M, Kuipers EJ, et al.. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med. 2019, 171:805-22. 10.7326\/M19-1795","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.11.014","article-title":"Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)","volume":"85","author":"Abrignani MG","year":"2021","unstructured":"Abrignani MG, Gatta L, Gabrielli D, et al.. Gastroprotection in patients on antiplatelet and\/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021, 85:1-13. 10.1016\/j.ejim.2020.11.014","journal-title":"Eur J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i11.1673","article-title":"Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy","volume":"19","author":"Iwamoto J","year":"2013","unstructured":"Iwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol. 2013, 19:1673-82. 10.3748\/wjg.v19.i11.1673","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force","volume":"164","author":"Whitlock EP","year":"2016","unstructured":"Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016, 164:826-35. 10.7326\/M15-2112","journal-title":"Ann Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.18-16","article-title":"Dual antiplatelet therapy does not affect the incidence of low-dose aspirin-induced small intestinal mucosal injury in patients after percutaneous coronary intervention for coronary stenosis: a multicenter cross-sectional study","volume":"63","author":"Hara A","year":"2018","unstructured":"Hara A, Ota K, Takeuchi T, et al.. Dual antiplatelet therapy does not affect the incidence of low-dose aspirin-induced small intestinal mucosal injury in patients after percutaneous coronary intervention for coronary stenosis: a multicenter cross-sectional study. J Clin Biochem Nutr. 2018, 63:224-9. 10.3164\/jcbn.18-16","journal-title":"J Clin Biochem Nutr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000593","article-title":"Proton pump inhibition in patients treated with novel antithrombotic drugs: should we worry about thrombosis?","volume":"72","author":"Bolek T","year":"2018","unstructured":"Bolek T, Samo\u0161 M, \u0160kor\u0148ov\u00e1 I, et al.. Proton pump inhibition in patients treated with novel antithrombotic drugs: should we worry about thrombosis?. J Cardiovasc Pharmacol. 2018, 72:71-6. 10.1097\/FJC.0000000000000593","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.07.004","article-title":"Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism","volume":"56","author":"Bonello L","year":"2010","unstructured":"Bonello L, Armero S, Ait Mokhtar O, et al.. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. J Am Coll Cardiol. 2010, 56:1630-6. 10.1016\/j.jacc.2010.07.004","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel PA","year":"2003","unstructured":"Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003, 107:2908-13. 10.1161\/01.CIR.0000072771.11429.83","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13316","article-title":"Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry","volume":"14","author":"Alexopoulos D","year":"2016","unstructured":"Alexopoulos D, Xanthopoulou I, Deftereos S, et al.. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. J Thromb Haemost. 2016, 14:1146-54. 10.1111\/jth.13316","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted S","year":"2006","unstructured":"Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006, 27:1038-47. 10.1093\/eurheartj\/ehi754","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.0612","article-title":"Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial","volume":"3","author":"Berwanger O","year":"2018","unstructured":"Berwanger O, Nicolau JC, Carvalho AC, et al.. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol. 2018, 3:391-9. 10.1001\/jamacardio.2018.0612","journal-title":"JAMA Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.156","article-title":"Long-term PPI use: balancing potential harms and documented benefits","volume":"111","author":"Laine L","year":"2016","unstructured":"Laine L, Nagar A. Long-term PPI use: balancing potential harms and documented benefits. Am J Gastroenterol. 2016, 111:913-5. 10.1038\/ajg.2016.156","journal-title":"Am J Gastroenterol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2523-4","article-title":"Only full adherence to proton pump inhibitors protects against drug-induced upper gastrointestinal bleeding","volume":"74","author":"Ruiz B","year":"2018","unstructured":"Ruiz B, Aguirre U, Estany-Gestal A, et al.. Only full adherence to proton pump inhibitors protects against drug-induced upper gastrointestinal bleeding. Eur J Clin Pharmacol. 2018, 74:1503-11. 10.1007\/s00228-018-2523-4","journal-title":"Eur J Clin Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03780.x","article-title":"Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study","volume":"28","author":"Mass\u00f3 Gonz\u00e1lez EL","year":"2008","unstructured":"Mass\u00f3 Gonz\u00e1lez EL, Garc\u00eda Rodr\u00edguez LA. Proton pump inhibitors reduce the long-term risk of recurrent upper gastrointestinal bleeding: an observational study. Aliment Pharmacol Ther. 2008, 28:629-37. 10.1111\/j.1365-2036.2008.03780.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.09.006","article-title":"Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin","volume":"152","author":"Chan FK","year":"2017","unstructured":"Chan FK, Kyaw M, Tanigawa T, et al.. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology. 2017, 152:105-10. 10.1053\/j.gastro.2016.09.006","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.264.hra","article-title":"PPIs prevent aspirin-induced gastrointestinal bleeding better than H2RAs. A systematic review and meta-analysis","volume":"26","author":"Szab\u00f3 IL","year":"2017","unstructured":"Szab\u00f3 IL, M\u00e1tics R, Hegyi P, et al.. PPIs prevent aspirin-induced gastrointestinal bleeding better than H2RAs. A systematic review and meta-analysis. J Gastrointestin Liver Dis. 2017, 26:395-402. 10.15403\/jgld.2014.1121.264.hra","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000489165","article-title":"H2 receptor antagonists versus proton pump inhibitors in patients on dual antiplatelet therapy for coronary artery disease: a systematic review","volume":"140","author":"Almufleh A","year":"2018","unstructured":"Almufleh A, Ramirez FD, So D, Le May M, Chong AY, Torabi N, Hibbert B. H2 receptor antagonists versus proton pump inhibitors in patients on dual antiplatelet therapy for coronary artery disease: a systematic review. Cardiology. 2018, 140:115-23. 10.1159\/000489165","journal-title":"Cardiology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.11.017","article-title":"Proton pump inhibitors and cardiovascular adverse effects: real or surreal worries?","volume":"72","author":"Manolis AA","year":"2020","unstructured":"Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: real or surreal worries?. Eur J Intern Med. 2020, 72:15-26. 10.1016\/j.ejim.2019.11.017","journal-title":"Eur J Intern Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000580","article-title":"Proton pump inhibitors: placing putative adverse effects in proper perspective","volume":"35","author":"Schubert ML","year":"2019","unstructured":"Schubert ML. Proton pump inhibitors: placing putative adverse effects in proper perspective. Curr Opin Gastroenterol. 2019, 35:509-16. 10.1097\/MOG.0000000000000580","journal-title":"Curr Opin Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5492\/wjccm.v4.i1.40","article-title":"Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy","volume":"4","author":"Yasuda H","year":"2015","unstructured":"Yasuda H, Matsuo Y, Sato Y, et al.. Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy. World J Crit Care Med. 2015, 4:40-6. 10.5492\/wjccm.v4.i1.40","journal-title":"World J Crit Care Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li L","year":"2017","unstructured":"Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017, 390:490-9. 10.1016\/S0140-6736(17)30770-5","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-018-1827-9","article-title":"Is proton pump inhibitors' prophylaxis indicated for patients on antiplatelet therapy?","volume":"13","author":"Porta L","year":"2018","unstructured":"Porta L, Baorda F, Fusco A. Is proton pump inhibitors' prophylaxis indicated for patients on antiplatelet therapy?. Intern Emerg Med. 2018, 13:585-7. 10.1007\/s11739-018-1827-9","journal-title":"Intern Emerg Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008226","article-title":"Bleeding risk, dual antiplatelet therapy cessation, and adverse events after percutaneous coronary intervention: the PARIS Registry","volume":"13","author":"Sorrentino S","year":"2020","unstructured":"Sorrentino S, Sartori S, Baber U, et al.. Bleeding risk, dual antiplatelet therapy cessation, and adverse events after percutaneous coronary intervention: the PARIS Registry. Circ Cardiovasc Interv. 2020, 13:e008226. 10.1161\/CIRCINTERVENTIONS.119.008226","journal-title":"Circ Cardiovasc Interv"},{"key":"ref34","article-title":"Logistic regression analysis of risk factors for upper gastrointestinal bleeding induced by PCI in combination with double antiplatelet therapy for STEMI patients","volume":"83","author":"Tang B","year":"2020","unstructured":"Tang B, Xiao S. Logistic regression analysis of risk factors for upper gastrointestinal bleeding induced by PCI in combination with double antiplatelet therapy for STEMI patients. Acta Gastroenterol Belg. 2020, 83:245-8.","journal-title":"Acta Gastroenterol Belg"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2564-8","article-title":"Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016","volume":"75","author":"Farhat N","year":"2019","unstructured":"Farhat N, Haddad N, Crispo J, et al.. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016. Eur J Clin Pharmacol. 2019, 75:227-35. 10.1007\/s00228-018-2564-8","journal-title":"Eur J Clin Pharmacol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested TS","year":"2019","unstructured":"Sehested TS, Carlson N, Hansen PW, et al.. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J. 2019, 40:1963-70. 10.1093\/eurheartj\/ehz104","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde WJ","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, et al.. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013, 381:1107-15. 10.1016\/S0140-6736(12)62177-1","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies","volume":"11","author":"Garc\u00eda Rodr\u00edguez LA","year":"2016","unstructured":"Garc\u00eda Rodr\u00edguez LA, Mart\u00edn-P\u00e9rez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS One. 2016, 11:e0160046. 10.1371\/journal.pone.0160046","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237022","article-title":"Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study","volume":"15","author":"Bouget J","year":"2020","unstructured":"Bouget J, Balusson F, Viglino D, Roy PM, Lacut K, Pavageau L, Oger E. Major bleeding risk and mortality associated with antiplatelet drugs in real-world clinical practice. A prospective cohort study. PLoS One. 2020, 15:e0237022. 10.1371\/journal.pone.0237022","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1483-x","article-title":"A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients","volume":"53","author":"Sugisaki N","year":"2018","unstructured":"Sugisaki N, Iwakiri R, Tsuruoka N, et al.. A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients. J Gastroenterol. 2018, 53:1253-60. 10.1007\/s00535-018-1483-x","journal-title":"J Gastroenterol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"W\u00fcrtz M","year":"2010","unstructured":"W\u00fcrtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart. 2010, 96:368-71. 10.1136\/hrt.2009.181107","journal-title":"Heart"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2017.01.006","article-title":"Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention","volume":"42","author":"Lavie CJ","year":"2017","unstructured":"Lavie CJ, Howden CW, Scheiman J, Tursi J. Upper gastrointestinal toxicity associated with long-term aspirin therapy: consequences and prevention. Curr Probl Cardiol. 2017, 42:146-64. 10.1016\/j.cpcardiol.2017.01.006","journal-title":"Curr Probl Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.05.051","article-title":"Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United Kingdom primary care","volume":"112","author":"Mart\u00edn Merino E","year":"2013","unstructured":"Mart\u00edn Merino E, Johansson S, Nagy P, Garc\u00eda Rodr\u00edguez LA. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United Kingdom primary care. Am J Cardiol. 2013, 112:1075-82. 10.1016\/j.amjcard.2013.05.051","journal-title":"Am J Cardiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel","volume":"180","author":"Juurlink DN","year":"2009","unstructured":"Juurlink DN, Gomes T, Ko DT, et al.. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009, 180:713-8. 10.1503\/cmaj.082001","journal-title":"CMAJ"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.08.001","article-title":"Concomitant use of proton pump inhibitors and clopidogrel is not associated with adverse outcomes after ischemic stroke in Chinese population","volume":"25","author":"Yi X","year":"2016","unstructured":"Yi X, Zhou Q, Wang C, Lin J, Cheng W, Chi L. Concomitant use of proton pump inhibitors and clopidogrel is not associated with adverse outcomes after ischemic stroke in Chinese population. J Stroke Cerebrovasc Dis. 2016, 25:2859-67. 10.1016\/j.jstrokecerebrovasdis.2016.08.001","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.05.017","article-title":"Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes trial","volume":"170","author":"Nicolau JC","year":"2015","unstructured":"Nicolau JC, Bhatt DL, Roe MT, et al.. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes trial. Am Heart J. 2015, 170:683-94. 10.1016\/j.ahj.2015.05.017","journal-title":"Am Heart J"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0718-z","article-title":"Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression","volume":"14","author":"Scarpignato C","year":"2016","unstructured":"Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016, 14:179. 10.1186\/s12916-016-0718-z","journal-title":"BMC Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003824","article-title":"Impact of proton pump inhibitor use on the comparative effectiveness and safety of prasugrel versus clopidogrel: insights from the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study","volume":"5","author":"Jackson LR 2nd","year":"2016","unstructured":"Jackson LR 2nd, Peterson ED, McCoy LA, et al.. Impact of proton pump inhibitor use on the comparative effectiveness and safety of prasugrel versus clopidogrel: insights from the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. J Am Heart Assoc. 2016, 5:e003824. 10.1161\/JAHA.116.003824","journal-title":"J Am Heart Assoc"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2016.03.007","article-title":"Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome","volume":"13","author":"Yan Y","year":"2016","unstructured":"Yan Y, Wang X, Fan JY, et al.. Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome. J Geriatr Cardiol. 2016, 13:209-17. 10.11909\/j.issn.1671-5411.2016.03.007","journal-title":"J Geriatr Cardiol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvy030","article-title":"Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry","volume":"5","author":"Hoedemaker NP","year":"2019","unstructured":"Hoedemaker NP, Damman P, Ottervanger JP, et al.. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry. Eur Heart J Cardiovasc Pharmacother. 2019, 5:127-38. 10.1093\/ehjcvp\/pvy030","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2016.03.042","article-title":"Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial","volume":"129","author":"Vaduganathan M","year":"2016","unstructured":"Vaduganathan M, Cannon CP, Cryer BL, et al.. Efficacy and safety of proton-pump inhibitors in high-risk cardiovascular subsets of the COGENT trial. Am J Med. 2016, 129:1002-5. 10.1016\/j.amjmed.2016.03.042","journal-title":"Am J Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.12.068","article-title":"Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy","volume":"67","author":"Vaduganathan M","year":"2016","unstructured":"Vaduganathan M, Bhatt DL, Cryer BL, et al.. Proton-pump inhibitors reduce gastrointestinal events regardless of aspirin dose in patients requiring dual antiplatelet therapy. J Am Coll Cardiol. 2016, 67:1661-71. 10.1016\/j.jacc.2015.12.068","journal-title":"J Am Coll Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001125","article-title":"Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis","volume":"30","author":"Khan MY","year":"2018","unstructured":"Khan MY, Siddiqui WJ, Alvarez C, Aggarwal S, Hasni SF, Ahmad A, Eisen H. Reduction in postpercutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018, 30:847-53. 10.1097\/MEG.0000000000001125","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3693","article-title":"Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI","volume":"12","author":"Wei P","year":"2016","unstructured":"Wei P, Zhang YG, Ling L, et al.. Effects of the short-term application of pantoprazole combined with aspirin and clopidogrel in the treatment of acute STEMI. Exp Ther Med. 2016, 12:2861-4. 10.3892\/etm.2016.3693","journal-title":"Exp Ther Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2019.02.002","article-title":"Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease","volume":"20","author":"Khan SU","year":"2019","unstructured":"Khan SU, Lone AN, Asad ZU, et al.. Meta-analysis of efficacy and safety of proton pump inhibitors with dual antiplatelet therapy for coronary artery disease. Cardiovasc Revasc Med. 2019, 20:1125-33. 10.1016\/j.carrev.2019.02.002","journal-title":"Cardiovasc Revasc Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009638","article-title":"Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis","volume":"97","author":"Hu W","year":"2018","unstructured":"Hu W, Tong J, Kuang X, Chen W, Liu Z. Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: a meta-analysis. Medicine (Baltimore). 2018, 97:e9638. 10.1097\/MD.0000000000009638","journal-title":"Medicine (Baltimore)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000934","article-title":"Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy","volume":"29","author":"Jensen BES","year":"2017","unstructured":"Jensen BES, Hansen JM, Larsen KS, Junker AB, Lassen JF, Jensen SE, Schaffalitzky de Muckadell OB. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. Eur J Gastroenterol Hepatol. 2017, 29:1118-25. 10.1097\/MEG.0000000000000934","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.01.015","article-title":"Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia study trial","volume":"174","author":"Gargiulo G","year":"2016","unstructured":"Gargiulo G, Costa F, Ariotti S, et al.. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: insights from the prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia study trial. Am Heart J. 2016, 174:95-102. 10.1016\/j.ahj.2016.01.015","journal-title":"Am Heart J"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.220304","article-title":"Impact of proton-pump inhibitors on the pharmacodynamic effect and clinical outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary intervention: a propensity score analysis","volume":"130","author":"Zhu P","year":"2017","unstructured":"Zhu P, Gao Z, Tang XF, et al.. Impact of proton-pump inhibitors on the pharmacodynamic effect and clinical outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary intervention: a propensity score analysis. Chin Med J (Engl). 2017, 130:2899-905. 10.4103\/0366-6999.220304","journal-title":"Chin Med J (Engl)"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001014","article-title":"Systematic review and meta-analysis: the effects of prophylactic proton pump inhibitor treatment in patients with coronary heart disease receiving dual antiplatelet therapy","volume":"77","author":"Li Y","year":"2021","unstructured":"Li Y, Ren X, Fang Z. Systematic review and meta-analysis: the effects of prophylactic proton pump inhibitor treatment in patients with coronary heart disease receiving dual antiplatelet therapy. J Cardiovasc Pharmacol. 2021, 77:835-61. 10.1097\/FJC.0000000000001014","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.11909\/j.issn.1671-5411.2020.11.008","article-title":"Impact of proton pump inhibitors on clinical outcomes in patients after acute myocardial infarction: a propensity score analysis from China Acute Myocardial Infarction (CAMI) registry","volume":"17","author":"Shi WC","year":"2020","unstructured":"Shi WC, Gao SD, Yang JG, et al.. Impact of proton pump inhibitors on clinical outcomes in patients after acute myocardial infarction: a propensity score analysis from China Acute Myocardial Infarction (CAMI) registry. J Geriatr Cardiol. 2020, 17:659-65. 10.11909\/j.issn.1671-5411.2020.11.008","journal-title":"J Geriatr Cardiol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024366","article-title":"Ethnic variance on long term clinical outcomes of concomitant use of proton pump inhibitors and clopidogrel in patients with stent implantation: a PRISMA-complaint systematic review with meta-analysis","volume":"100","author":"Shi W","year":"2021","unstructured":"Shi W, Yan L, Yang J, Yu M. Ethnic variance on long term clinical outcomes of concomitant use of proton pump inhibitors and clopidogrel in patients with stent implantation: a PRISMA-complaint systematic review with meta-analysis. Medicine (Baltimore). 2021, 100:e24366. 10.1097\/MD.0000000000024366","journal-title":"Medicine (Baltimore)"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26716","article-title":"Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: results from the PARIS registry","volume":"89","author":"Chandrasekhar J","year":"2017","unstructured":"Chandrasekhar J, Bansilal S, Baber U, et al.. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: results from the PARIS registry. Catheter Cardiovasc Interv. 2017, 89:E217-25. 10.1002\/ccd.26716","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.110.958561","article-title":"First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies","volume":"3","author":"Tantry US","year":"2010","unstructured":"Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010, 3:556-66. 10.1161\/CIRCGENETICS.110.958561","journal-title":"Circ Cardiovasc Genet"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001134","article-title":"Trials of dual antiplatelet therapy after percutaneous coronary intervention lack strategies to ensure appropriate gastroprotection","volume":"116","author":"Kurlander JE","year":"2021","unstructured":"Kurlander JE, Barnes GD, Sukul D, et al.. Trials of dual antiplatelet therapy after percutaneous coronary intervention lack strategies to ensure appropriate gastroprotection. Am J Gastroenterol. 2021, 116:821-4. 10.14309\/ajg.0000000000001134","journal-title":"Am J Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2019.19057","article-title":"NSAID, antiaggregant, and\/or anticoagulant-related upper gastrointestinal bleeding: is there any change in prophylaxis rate after a 10-year period?","volume":"30","author":"Din\u00e7er D","year":"2019","unstructured":"Din\u00e7er D, Ulukal Karanc\u0131 E, Ak\u0131n M, Adan\u0131r H. NSAID, antiaggregant, and\/or anticoagulant-related upper gastrointestinal bleeding: is there any change in prophylaxis rate after a 10-year period?. Turk J Gastroenterol. 2019, 30:505-10. 10.5152\/tjg.2019.19057","journal-title":"Turk J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/70774-co-prescription-of-dual-antiplatelet-therapy-and-proton-pump-inhibitors-current-guidelines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:44:55Z","timestamp":1707507895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/70774-co-prescription-of-dual-antiplatelet-therapy-and-proton-pump-inhibitors-current-guidelines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":66,"URL":"https:\/\/doi.org\/10.7759\/cureus.21885","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}